{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:59:23Z","timestamp":1794959963963,"version":"4.9.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Detailed information on the onset, frequency, and severity of bleeding in nonsevere hemophilia is limited. We aimed to assess the bleeding phenotype of persons with nonsevere hemophilia and to analyze the association between baseline factor VIII\/IX (FVIII\/IX) levels and the joint bleeding rate. In the DYNAMO (Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild\u00a0Hemophilia\u00a0A and B) study, an international multicenter cohort, we included males with nonsevere hemophilia (FVIII\/IX, 0.02-0.35 IU\/mL) aged 12 to 55 years. Information on age at first treated (joint) bleed, annual bleeding rates (ABRs), and annual joint bleeding rates (AJBRs) was collected from the medical files. The association between baseline FVIII\/IX levels and the joint bleeding rate was assessed by using a frailty model for recurrent events. In total, 304 persons (70 with moderate hemophilia and 234 with mild hemophilia) were included. The median age was 38 years (interquartile range [IQR], 25-49 years), and the median baseline FVIII\/IX level was 0.12 IU\/mL (IQR, 0.05-0.21 IU\/mL). In total, 245 (81%) persons had experienced at least 1 bleed, and 156 (51%) had experienced at least 1 joint bleed. The median age at first bleed and first joint bleed was 8 and 10 years, respectively. The median ABR and AJBR was 0.2 (IQR, 0.1-0.5) and 0.0 (IQR, 0.0-0.2). From baseline FVIII\/IX levels 0.02 to 0.05 IU\/mL to &amp;gt;0.25 IU\/mL, the median ABR decreased from 0.6 (IQR, 0.2-1.4) to 0.1 (IQR, 0.0-0.2) and the AJBR from 0.2 (IQR, 0.0-0.4) to 0.0 (IQR, 0.0-0.0). Baseline FVIII\/IX was inversely associated with the joint bleeding rate (P &amp;lt; .001). Low bleeding rates were observed in persons with nonsevere hemophilia. However, one-half of all adolescents and adults had experienced a joint bleed.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007620","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T18:33:17Z","timestamp":1652121197000},"page":"4256-4265","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["The bleeding phenotype in people with nonsevere hemophilia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4988-1462","authenticated-orcid":false,"given":"Fabienne R.","family":"Kloosterman","sequence":"first","affiliation":[{"name":"1Emma Children\u2019s Hospital, Pediatric Hematology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-1229","authenticated-orcid":false,"given":"Anne-Fleur","family":"Zwagemaker","sequence":"additional","affiliation":[{"name":"1Emma Children\u2019s Hospital, Pediatric Hematology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-9706","authenticated-orcid":false,"given":"Catherine N.","family":"Bagot","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9871-433X","authenticated-orcid":false,"given":"Erik A. M.","family":"Beckers","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"4Department of Oncology, Center for Bleeding Disorders, Careggi University Hospital, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-2995","authenticated-orcid":false,"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[{"name":"5Department of Pediatric Hematology, Erasmus University Medical Center\u2013Sophia Children\u2019s Hospital, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Collins","sequence":"additional","affiliation":[{"name":"6Cardiff Haemophilia Centre, School of Medicine, Cardiff University, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-6828","authenticated-orcid":false,"given":"Charles","family":"Hay","sequence":"additional","affiliation":[{"name":"7University Department of Haematology, The University of Manchester, Manchester Royal Infirmary, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Hof","sequence":"additional","affiliation":[{"name":"8Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Laros-van Gorkom","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Erasmus University Medical Center, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-6421","authenticated-orcid":false,"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-0465","authenticated-orcid":false,"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[{"name":"12Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"13Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-0802","authenticated-orcid":false,"given":"Susan","family":"Shapiro","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Oxford University Hospitals NHS Foundation, Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom;"},{"name":"15Radcliffe Department of Medicine, Oxford University, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-9062","authenticated-orcid":false,"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[{"name":"16Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[{"name":"1Emma Children\u2019s Hospital, Pediatric Hematology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands;"},{"name":"17Department of Molecular Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-4122","authenticated-orcid":false,"given":"Samantha C.","family":"Gouw,","sequence":"additional","affiliation":[{"name":"1Emma Children\u2019s Hospital, Pediatric Hematology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"11","key":"2022072115254657800_B1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost."},{"key":"2022072115254657800_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia."},{"issue":"5","key":"2022072115254657800_B3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13777","article-title":"Burden of mild haemophilia A: systematic literature review","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia."},{"issue":"16","key":"2022072115254657800_B4","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv."},{"issue":"5","key":"2022072115254657800_B5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/hae.14114","article-title":"Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B\u2014the MoHem study","volume":"26","author":"M\u00e5seide","year":"2020","journal-title":"Haemophilia."},{"key":"2022072115254657800_B6","first-page":"s330","article-title":"Outcome in moderate haemophilia","volume":"12","author":"den Uijl","year":"2014","journal-title":"Blood Transfus."},{"issue":"1","key":"2022072115254657800_B7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01837.x","article-title":"Clinical outcome of moderate haemophilia compared with severe and mild haemophilia","volume":"15","author":"den Uijl","year":"2009","journal-title":"Haemophilia."},{"issue":"6","key":"2022072115254657800_B8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia."},{"issue":"2","key":"2022072115254657800_B9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2516.2011.02617.x","article-title":"The natural history of mild haemophilia: a 30-year single centre experience","volume":"18","author":"Tagliaferri","year":"2012","journal-title":"Haemophilia."},{"issue":"3","key":"2022072115254657800_B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2516.2009.02001.x","article-title":"Haemophilia in Spain","volume":"15","author":"Aznar","year":"2009","journal-title":"Haemophilia."},{"issue":"6","key":"2022072115254657800_B11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","article-title":"Burden of illness: direct and indirect costs among persons with hemophilia A in the United States","volume":"18","author":"Zhou","year":"2015","journal-title":"J Med Econ."},{"issue":"10","key":"2022072115254657800_B12","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/jth.15424","article-title":"Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019","volume":"19","author":"Hassan","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022072115254657800_B13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia."},{"key":"2022072115254657800_B14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jth.12248","article-title":"Bleeders, bleeding rates, and bleeding score","volume":"11","author":"Tosetto","year":"2013","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022072115254657800_B15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra\u00ae) for hemophilia A in Europe: data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"Krumb","year":"2021","journal-title":"Haemophilia."},{"issue":"2","key":"2022072115254657800_B16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hae.14201","article-title":"Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level?","volume":"27","author":"Collins","year":"2021","journal-title":"Haemophilia."},{"issue":"5","key":"2022072115254657800_B17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in\u00a0vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia."},{"issue":"11","key":"2022072115254657800_B18","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1177\/0962280220921889","article-title":"A tutorial on frailty models","volume":"29","author":"Balan","year":"2020","journal-title":"Stat Methods Med Res."},{"key":"2022072115254657800_B19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2021-152551","article-title":"Bleeding data across baseline FIX expression levels in people with hemophilia B: an analysis using the \u2018Factor Expression Study.\u2019","volume":"138","author":"Burke","year":"2021","journal-title":"Blood."},{"issue":"6","key":"2022072115254657800_B20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med."},{"issue":"5","key":"2022072115254657800_B21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol."},{"issue":"5","key":"2022072115254657800_B22","doi-asserted-by":"crossref","first-page":"e12571","DOI":"10.1002\/rth2.12571","article-title":"Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: a single-center report","volume":"5","author":"Warren","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"key":"2022072115254657800_B23","author":"N\u00e9grier"},{"issue":"5","key":"2022072115254657800_B24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thromb Haemost."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4256\/1909079\/advancesadv2022007620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4256\/1909079\/advancesadv2022007620.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T15:29:10Z","timestamp":1658417350000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4256\/485196\/The-bleeding-phenotype-in-people-with-nonsevere"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":24,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007620","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}